Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 298

1.

In vitro and in vivo anti-leukemic activity of the peptidase-potentiated alkylator melflufen in acute myeloid leukemia.

Strese S, Hassan SB, Velander E, Haglund C, Höglund M, Larsson R, Gullbo J.

Oncotarget. 2016 Dec 10. doi: 10.18632/oncotarget.13856. [Epub ahead of print]

2.

Clonal Variation in Drug and Radiation Response among Glioma-Initiating Cells Is Linked to Proneural-Mesenchymal Transition.

Segerman A, Niklasson M, Haglund C, Bergström T, Jarvius M, Xie Y, Westermark A, Sönmez D, Hermansson A, Kastemar M, Naimaie-Ali Z, Nyberg F, Berglund M, Sundström M, Hesselager G, Uhrbom L, Gustafsson M, Larsson R, Fryknäs M, Segerman B, Westermark B.

Cell Rep. 2016 Dec 13;17(11):2994-3009. doi: 10.1016/j.celrep.2016.11.056.

3.

Systemic matrix metalloproteinase-8 response in chronic tonsillitis.

Ilmarinen T, Lont T, Hagström J, Tervahartiala T, Sorsa T, Haglund C, Munck-Wickland E, Ramqvist T, Dalianis T, Aaltonen LM.

Infect Dis (Lond). 2016 Nov 2:1-6. [Epub ahead of print]

PMID:
27804311
4.

The prognostic role of systemic inflammation in patients undergoing resection of colorectal liver metastases: C-reactive protein (CRP) is a strong negative prognostic biomarker.

Køstner AH, Kersten C, Löwenmark T, Ydsten KA, Peltonen R, Isoniemi H, Haglund C, Gunnarsson U, Isaksson B.

J Surg Oncol. 2016 Dec;114(7):895-899. doi: 10.1002/jso.24415.

PMID:
27696432
5.

Endoscopic sphincterotomy and risk of cholangiocarcinoma: a population-based cohort study in Finland and Sweden.

Strömberg C, Böckelman C, Song H, Ye W, Pukkala E, Haglund C, Nilsson M.

Endosc Int Open. 2016 Oct;4(10):E1096-E1100.

6.

Carbonic anhydrase enzymes II, VII, IX and XII in colorectal carcinomas.

Viikilä P, Kivelä AJ, Mustonen H, Koskensalo S, Waheed A, Sly WS, Pastorek J, Pastorekova S, Parkkila S, Haglund C.

World J Gastroenterol. 2016 Sep 28;22(36):8168-77. doi: 10.3748/wjg.v22.i36.8168.

7.

Systemic Inflammatory Response and Elevated Tumour Markers Predict Worse Survival in Resectable Pancreatic Ductal Adenocarcinoma.

Salmiheimo A, Mustonen H, Stenman UH, Puolakkainen P, Kemppainen E, Seppänen H, Haglund C.

PLoS One. 2016 Sep 15;11(9):e0163064. doi: 10.1371/journal.pone.0163064.

8.

Combination screening in vitro identifies synergistically acting KP372-1 and cytarabine against acute myeloid leukemia.

Österroos A, Kashif M, Haglund C, Blom K, Höglund M, Andersson C, Gustafsson MG, Eriksson A, Larsson R.

Biochem Pharmacol. 2016 Oct 15;118:40-49. doi: 10.1016/j.bcp.2016.08.020.

PMID:
27565890
9.

Increased MMP-7 expression in biliary epithelium and serum underpins native liver fibrosis after successful portoenterostomy in biliary atresia.

Kerola A, Lampela H, Lohi J, Heikkilä P, Mutanen A, Hagström J, Tervahartiala T, Sorsa T, Haglund C, Jalanko H, Pakarinen MP.

J Pathol Clin Res. 2016 May 12;2(3):187-98. doi: 10.1002/cjp2.50.

10.

PROX1 and β-catenin are prognostic markers in pancreatic ductal adenocarcinoma.

Saukkonen K, Hagström J, Mustonen H, Juuti A, Nordling S, Kallio P, Alitalo K, Seppänen H, Haglund C.

BMC Cancer. 2016 Jul 13;16:472. doi: 10.1186/s12885-016-2497-5.

11.

HuR in pheochromocytomas and paragangliomas - overexpression in verified malignant tumors.

Leijon H, Salmenkivi K, Heiskanen I, Hagström J, Louhimo J, Heikkilä P, Ristimäki A, Paavonen T, Metso S, Mäenpää H, Haglund C, Arola J.

APMIS. 2016 Sep;124(9):757-63. doi: 10.1111/apm.12571.

PMID:
27357268
12.

The Results of Pancreatic Resections and Long-Term Survival for Pancreatic Ductal Adenocarcinoma: A Single-Institution Experience.

Seppänen H, Juuti A, Mustonen H, Haapamäki C, Nordling S, Carpelan-Holmström M, Sirén J, Luettges J, Haglund C, Kiviluoto T.

Scand J Surg. 2016 Apr 29. pii: 1457496916645963. [Epub ahead of print]

PMID:
27130378
13.

Does securin expression have significance in prognostication of oral tongue cancer? A pilot study.

Heikkinen I, Almangush A, Hagström J, Bello IO, Kauppila JH, Mäkinen LK, Haglund C, Nieminen P, Salo T, Leivo I.

Eur Arch Otorhinolaryngol. 2016 Nov;273(11):3905-3911.

PMID:
27091335
14.

Association of BMI-1 and p16 as prognostic factors for head and neck carcinomas.

Lundberg M, Renkonen S, Haglund C, Mattila PS, Leivo I, Hagström J, Mäkitie AA.

Acta Otolaryngol. 2016;136(5):501-5. doi: 10.3109/00016489.2015.1122227.

PMID:
27052966
15.

REG4 Is Highly Expressed in Mucinous Ovarian Cancer: A Potential Novel Serum Biomarker.

Lehtinen L, Vesterkvist P, Roering P, Korpela T, Hattara L, Kaipio K, Mpindi JP, Hynninen J, Auranen A, Davidson B, Haglund C, Iljin K, Grenman S, Siitari H, Carpen O.

PLoS One. 2016 Mar 16;11(3):e0151590. doi: 10.1371/journal.pone.0151590.

16.

Expression of ODC Antizyme Inhibitor 2 (AZIN2) in Human Secretory Cells and Tissues.

Rasila T, Lehtonen A, Kanerva K, Mäkitie LT, Haglund C, Andersson LC.

PLoS One. 2016 Mar 10;11(3):e0151175. doi: 10.1371/journal.pone.0151175.

17.

The Use of Blood Products in Adult Patients with Burns.

Koljonen V, Tuimala J, Haglund C, Tukiainen E, Vuola J, Juvonen E, Lauronen J, Krusius T.

Scand J Surg. 2016 Sep;105(3):178-85. doi: 10.1177/1457496915622127.

PMID:
26929291
18.

Toll-like receptor 5 and 7 expression in adenoid cystic carcinoma of major salivary glands.

Hirvonen K, Bäck L, Haglund C, Leivo I, Jouhi L, Mäkitie AA, Hagström J.

Tumour Biol. 2016 Aug;37(8):10959-64. doi: 10.1007/s13277-016-4971-8.

PMID:
26888781
19.

Podocalyxin as a Prognostic Marker in Gastric Cancer.

Laitinen A, Böckelman C, Hagström J, Kokkola A, Fermér C, Nilsson O, Haglund C.

PLoS One. 2015 Dec 16;10(12):e0145079. doi: 10.1371/journal.pone.0145079.

20.

Transketolase-like protein 1 expression predicts poor prognosis in colorectal cancer.

Ahopelto K, Böckelman C, Hagström J, Koskensalo S, Haglund C.

Cancer Biol Ther. 2016;17(2):163-8. doi: 10.1080/15384047.2015.1121347.

Items per page

Supplemental Content

Loading ...
Support Center